Neuroscience

MemoMaster Unveiled: How This Memo Master Cutting-Edge Brain Support Supplement Is Redefining Focus and Memory Health for the Digital Era

Boost memory, focus & mental clarity with MemoMaster – a clinically inspired brain supplement for sharper thinking, sustained energy &...

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

Interim data from the IQIRVO® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers...

NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

ZURICH, Nov. 6, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a biotechnology company advancing transformative therapies for...

Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease

Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented...

BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder

New NIH grant awards $2.5 million over 5 years for mechanistic studyBURLINGTON, Mass. and JERUSALEM, Nov. 04, 2025 (GLOBE NEWSWIRE)...

Signant Health Appoints Internationally Recognized Cognitive Assessment Expert John Harrison to Further Advance Innovation in CNS Clinical Trials

PHILADELPHIA, Oct. 30, 2025 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today the...

Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence

New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite...

Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States

Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs INDIANAPOLIS, Oct. 29, 2025 /PRNewswire/ -- Eli...

error: Content is protected !!